"Immunotherapy Combination Improves OS Compared With Chemotherapy In Lung Cancer Subset" - John DeRosier
A combination of nivolumab and low-dose ipilimumab significantly improved OS compared with chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer, according to results of the randomized phase three CheckMate 227 study presented at European Society for Medical Oncology Congress. According to Nicholas Rohs, MD, assistant professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, who was not involved in the study, “I was pleasantly surprised to see these results, but I am not sure they are practice changing for me. Benefit was notably more pronounced for patients with high PD-L1-expressing tumors.” He added, “Given these patients often have good response from a well-tolerated single-agent immunotherapy regimen, my excitement in this subpopulation is modest.”
— Nicholas Rohs, MD, Assistant Professor of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, The Tisch Cancer Institute, Mount Sinai Health System